Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

血清肌酐与胱抑素C比值是接受新辅助免疫化疗的食管鳞状细胞癌患者的预后指标。

阅读:1

Abstract

BACKGROUND: This study aimed to explore the relationship between pretreatment serum creatinine to cystatin C ratio (CCR) and prognosis in patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT). METHODS: Two hundred and two ESCC patients who received NICT were included in the current retrospective study. The restricted cubic spline displayed the non-linear relationship between prognosis and CCR. The association between overall survival (OS)/disease-free survival (DFS) and CCR was also investigated. Kaplan-Meier methods and Cox proportional hazard regression analyses were employed. RESULTS: The connection between DFS/OS and CCR suggested that their interaction was non-linear. The restricted cubic spline (RCS) model identified 97.5 as the ideal cutoff point for CCR and divided it into 2 groups. Patients exhibiting low CCR demonstrated significantly worse 3-year DFS (48.5% vs. 74.3%, P<0.001) and OS (62.9% vs. 82.9%, P=0.001) compared to those with high CCR. The results indicated that CCR had prognostic significance for the ESCC cases stratified according to subgroup analyses. Compared to the low CCR group, subsequent multivariate analysis revealed that the high CCR group reduced the risk of recurrence by 56.0% (P=0.001) and the risk of death by 51.8% (P=0.013), respectively. CONCLUSION: The therapeutic efficacy of NICT for ESCC can be predicted by pretreatment CCR. Although the CCR may not have attained a very high quality, it still holds certain significance for clinical practice in ESCC patients undergoing NICT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。